According to study results presented at ASCO20 Virtual Scientific Program, a year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
According to study results presented at ASCO20 Virtual Scientific Program, a year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer.